HLB is continuing its upward trend for the third consecutive trading day, driven by the aftereffects of the U.S. Food and Drug Administration (FDA) approval of its bile duct cancer drug 'LYRFIGTU' (Ripiktu).

During trading on the 30th, HLB shares were trading at 40,500 won, up 300 won from the previous trading day, a gain of 0.75%. Market attention is focused on the stock's movement following the FDA approval.

According to a report by News1, a ceremony commemorating the FDA approval of Ripiktu was held on the 29th at HLB's Hakdong headquarters in Gangnam-gu, Seoul. Chairman Jin Yang-gon of HLB Group and other executives and employees attended to celebrate the FDA approval achievement together.

The FDA approval of Ripiktu marks one of the major milestones in the drug development business that HLB Group has pursued. As the stock has risen consecutively since the approval news, investors are also paying attention to the actual process of entering the U.S. market and the future commercialization schedule.

However, given the stock's consecutive short-term gains, trading volume and supply-demand changes should also be monitored going forward. Not only the drug approval itself, but also the actual start of sales, the pace of market penetration, and progress in follow-up clinical trials and the pipeline could influence the mid- to long-term stock price trend.

[This article is an informational piece based on publicly available corporate materials, securities firm analyses, and market data. It does not guarantee the rise or fall of any specific stock or recommend buying or selling. Securities firms' target prices and earnings forecasts may change depending on market conditions, and responsibility for losses arising from investment lies with the investor. AI was used for some sentences and data compilation.]